UCB (WBO:UCB) Beginning Cash Position : €456 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is UCB Beginning Cash Position?

UCB's Beginning Cash Position for the quarter that ended in Dec. 2023 was €456 Mil.

UCB's quarterly Beginning Cash Position increased from Dec. 2022 (€471 Mil) to Jun. 2023 (€859 Mil) but then declined from Jun. 2023 (€859 Mil) to Dec. 2023 (€456 Mil).

UCB's annual Beginning Cash Position declined from Dec. 2021 (€1,304 Mil) to Dec. 2022 (€1,244 Mil) and declined from Dec. 2022 (€1,244 Mil) to Dec. 2023 (€859 Mil).

UCB Beginning Cash Position Historical Data

The historical data trend for UCB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Beginning Cash Position Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

1,237.00

1,288.00

1,304.00

1,244.00

859.00

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial															542.00	1,244.00	471.00	859.00	456.00

UCB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

UCB Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of UCB's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (WBO:UCB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (WBO:UCB) Headlines

No Headlines